Alysse G.\u00a0<\/b>Wurcel<\/b><\/strong><\/p>\n<\/div>\n \u201cWe appreciate the limitations of race and ethnicity as classifications, especially in electronic health records; however, we were surprised that race and ethnicity had variable associations depending on the hospital system,\u201d Kimberly G. Blumenthal, MD, MSc<\/b>,<\/b> professor of medicine at Mayo Clinic College of Medicine and Science, and Alysse G. <\/b>Wurcel<\/b>, MD, MS, <\/b>associate professor of medicine at Boston University School of Medicine, told Healio in a statement.<\/p>\n
\u201cWithin one hospital system, Black patients were more likely to be delabeled, but within another hospital system, Black patients were less likely to be delabeled,\u201d they said. <\/p>\n
Using electronic health record data from January 2019 to April 2022, Blumenthal and <\/b>colleagues evaluated 77,047 primary care patients with any active or inactive penicillin allergy record at two health care systems (Mass General Brigham and Tufts Medicine) to uncover if there is a difference in penicillin allergy delabeling prevalence based on race.<\/p>\n
\u201cIt is known that penicillin allergy evaluation and delabeling improves clinical care, but access to delabeling is often limited to specialist allergy visits, which may not be routinely accessible,\u201d Blumenthal and Wurcel said. \u201cThere is also robust literature about how people\u2019s race and ethnicity can impact access to health care.<\/p>\n
\u201cThe association with race and ethnicity with access to penicillin allergy delabeling needed more investigation,\u201d they continued.<\/p>\n
A small proportion of patients in the total population were delabeled (6.8%), according to the study.<\/p>\n
In the Mass General Brigham group (n = 46,854; median age, 58 years; 70% women; 80% white; 6% Black; 4% Asian), 10% of patients were delabeled, which was significantly greater than the 3% of patients in the Tufts Medicine group (n = 30,193; median age, 58 years; 69% women; 82% white; 4% Black; 5% Asian).<\/p>\n
Researchers noted that allergy\/immunology visits were where most patients at Mass General Brigham underwent penicillin allergy delabeling (47%), and this differed from Tufts Medicine where primary care visits were where most patients underwent delabeling (43%). Delabeling during allergy\/immunology visits was reported for 5% of patients at Tufts Medicine, and delabeling during primary care visits was reported for 20% of patients at Mass General Brigham. <\/p>\n
Considering both systems, the odds for penicillin allergy delabeling were significantly reduced among Black vs. white patients (adjusted OR = 0.73; 95% CI, 0.64-0.84) and Asian vs. white patients (aOR = 0.76; 95% CI, 0.65-0.88).<\/p>\n
When broken down by health system, researchers continued to find significantly decreased odds for delabeling among Black vs. white patients (aOR = 0.63; 95% CI, 0.54-0.73) and Asian vs. white patients (aOR = 0.74; 95% CI, 0.63-0.88) in the Mass General Brigham group. <\/p>\n
Among Tufts Medicine patients, the link between Asian race and reduced odds for delabeling did not reach significance. Additionally, the odds for delabeling were significantly increased among Black vs. white patients in this health system (aOR = 1.57; 95% CI, 1.18-2.1), according to the study.<\/p>\n
\u201cWe found differences in delabeling for Black patients between institutions,\u201d Blumenthal and Wurcel told Healio.<\/p>\n
\u201cWe are intrigued by the heterogeneity,\u201d they added. \u201cThe next step of our research aims at digging in deeper to differences between institutions, such as availability of allergists, comfort of primary care clinicians with delabeling in ambulatory practices and other potentially important factors.\u201d<\/p>\n
Researchers did not observe any significant mediators in the link between Black race and lower odds for penicillin allergy delabeling among patients from Mass General Brigham. In contrast, the relationship between Asian race and delabeling prevalence was \u201cpartially explained\u201d by two mediators: non-English language preference (8%) and health care visits (up to 16%).<\/p>\n
Switching to patients from Tufts Medicine, the study identified two mediators in the link between Black race and elevated odds for delabeling: Health care visits (15%; allergy\/immunology visits, 39%; inpatient visits, 8%; emergency visits, 7%) and Charlson Comorbidity Index (CCI; 10%).<\/p>\n
Similar to Mass General Brigham, researchers found that the relationship between Asian race and delabeling prevalence was mediated by non-English language preference (61%) and health care visits (37%; inpatient visits, 9%; emergency visits, 13%), as well as CCI (7%). <\/p>\n
\u201cWe found that an important barrier to penicillin allergy delabeling is non-English language preference for Asian patients,\u201d Blumenthal and Wurcel told Healio. \u201cThis means that one of the reasons that Asian people may not be getting delabeling is because of the language barrier between patients and doctors.<\/p>\n
\u201cFuture studies should seek to understand the barriers and facilitators to delabeling and uncover methods to improve access to, and uptake of, penicillin allergy delabeling,\u201d Blumenthal and Wurcel added.<\/p>\n
For more information:<\/h2>\n Kimberly G. Blumenthal, MD, MSc,<\/b> <\/b>can be reached at blumenthal.kimberly@mayo.edu.<\/p>\n
Alysse <\/b>G. <\/b>Wurcel<\/b>,<\/b> MD, MS,<\/b> can be reached at alysse.wurcel@bmc.org. <\/p>\n\n
\n
Perspective<\/h2>\n Back to Top
\n
\n
\n <\/div>\n
Over 10% of the population has been labeled with a penicillin allergy. However, the majority of these diagnoses do not reflect true IgE-mediated drug allergy. For decades, allergists have strived to remove inaccurate labels to prevent downstream harm, but delabeling efforts have not reached all populations equally. This retrospective cohort study by Blumenthal and colleagues highlights the racial inequities in access to allergy care and delabeling of penicillin allergy in two different health systems.<\/default:p>The findings from this study are not surprising, as socioeconomic factors are known to disproportionately affect the health of historically marginalized groups, and allergic conditions are no exception. This study found that Black and Asian patients had overall reduced prevalence of penicillin allergy delabeling in comparison with white patients. However, there were differences appreciated between the different health care systems with Black patients being more likely to be delabeled at Tufts Medicine in comparison to Mass General Brigham. <\/default:p>Interestingly, the majority of penicillin allergy delabeling at Tufts Medicine was done by primary care offices compared with allergy and immunology at Mass General Brigham. Perhaps this is because there are fewer allergists on staff at Tufts Medicine, limiting access to allergy care with the onus falling on primary care providers. The authors also pointed out that Black patients at Tufts Medicine had increased health care utilization, which may provide more opportunities for penicillin allergy labels to be addressed.<\/default:p>Physicians can use these findings to improve care by being more aware and proactive of delabeling opportunities to avoid unintentionally reinforcing disparities as well as increased initiatives for standardized pathways for low-risk patients in both primary care and specialty settings.<\/default:p>Further studies should be completed to assess and address barriers to delabeling in order to improve equitable access amongst all groups.<\/default:p><\/p>\n\n
Victoria T. Nguyen, DO<\/strong><\/p>\n\nClinical Assistant Professor, Division of Allergy and Immunology, Department of Otolaryngology, The Ohio State University Wexner Medical Center<\/li>\n<\/ul><\/div>\n
Disclosures: <\/strong> Nguyen reports no relevant financial disclosures.
\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n\n
Sources\/Disclosures<\/h3>\n Source: <\/h2>\n Blumenthal KG, et al. Ann <\/i>Allergy <\/i>Asthma <\/i>Immunol<\/i>. 2025;doi:10.1016\/j.anai.2025.11.025.<\/p>\n\n
Disclosures: <\/strong>
<\/p>\n
\n
\n
<\/p>\n
Ask a clinical question<\/strong> and tap into Healio AI’s knowledge<\/strong> base.<\/p>\n
<\/p>\nPubMed, enrolling\/recruiting trials, guidelines<\/li>\n
<\/p>\n
Clinical Guidance, Healio CME, FDA news<\/li>\n
<\/p>\n
Healio’s exclusive daily news coverage of clinical data<\/li>\n
\n <\/ul>\n
Learn more<\/button>\n <\/div>\n<\/div>\n